Success of nano-vaccines against COVID-19: a transformation in nanomedicine.

Manoj Kumar SarangiSasmita PadhiGautam RathSitansu Sekhar NandaDong Kee Yi

Published in: Expert review of vaccines (2022)

The mRNA-based vaccines, with their tremendous efficacy of ~95% (under phase III-IV clinical trials) and distinct nanocarriers (LNPs), represent a new medical front alongside DNA and siRNA-based vaccines.

Keyphrases

phase iii
clinical trial
cancer therapy
open label
coronavirus disease
phase ii
sars cov
drug delivery
healthcare
double blind
cell free
single molecule
circulating tumor
randomized controlled trial
drug release
hyaluronic acid
respiratory syndrome coronavirus